Literature DB >> 20022206

Perioperative beta-blockers for vascular surgery patients.

Benjamin S Brooke1.   

Abstract

Perioperative beta-blocker therapy has been a heavily investigated and controversial topic during the past decade. Prior national consensus statements that recommended the routine use of these medications in patients undergoing high-risk surgical procedures have been called into question because of the results of recent clinical trials that involved heterogeneous groups of surgical patients. This article reviews the evidence for perioperative beta-blocker usage as it pertains to patients undergoing vascular surgery procedures. The weight of evidence suggests that beta-blockers lower the perioperative risk of myocardial ischemia or infarction and cardiovascular death among patients with clinical risk factors undergoing major vascular surgery. However, there appears to be a concurrent risk of adverse events associated with these medications if patients are not monitored properly during the perioperative period. Perioperative beta-blockers should continue to occupy a prominent role in the therapeutic armamentarium for improving outcomes among high-risk patients undergoing major vascular surgery. Copyright 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20022206     DOI: 10.1016/j.jvs.2009.09.057

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  2 in total

1.  A regional quality improvement effort to increase beta blocker administration before vascular surgery.

Authors:  Philip P Goodney; Jens Eldrup-Jorgensen; Brian W Nolan; Daniel J Bertges; Donald S Likosky; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2011-02-21       Impact factor: 4.268

Review 2.  Beta-blockers in vascular surgery patients: is the debate still going on?

Authors:  George Galyfos; Konstantinos Filis; Fragiska Sigala; Georgios Geropapas
Journal:  J Anesth       Date:  2016-08-12       Impact factor: 2.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.